Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online October 1, 2020.
Article Versions
- Latest version (March 15, 2020 - 04:00).
- You are currently viewing a Latest version of this article (October 1, 2020 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2020 The Journal of Rheumatology
Author Information
- Elisabeth Blaja,
- Suzana Jordan,
- Carmen-Marina Mihai,
- Rucsandra Dobrota,
- Mike Oliver Becker,
- Britta Maurer,
- Marco Matucci-Cerinic and
- Oliver Distler
- E. Blaja, MD, S. Jordan, PhD, C.M. Mihai, MD, PhD, R. Dobrota, MD, PhD, M.O. Becker, MD, B. Maurer, MD, O. Distler, Professor of Rheumatology, MD, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland; M. Matucci-Cerinic, Division of Rheumatology, University of Florence, Florence, Italy.
B. Maurer had grant/research support from AbbVie, Protagen, Novartis; congress support from Pfizer, Roche, Actelion, and MSD; and a consultancy relationship with Novartis. In addition, BM has a patent mir-29 for the treatment of systemic sclerosis (SSc) registered. The work of BM is supported by the Prof. Max Cloetta Foundation. O. Distler had a consultancy relationship and/or has received research funding from Actelion, Acceleron Pharma, Amgen, AnaMar, Baecon Discovery, Blade Therapeutics, Bayer, Boehringer Ingelheim, Catenion, CSL Behring, Curzion Pharmaceuticals, Ergonex, Glenmark Pharmaceuticals GSK, Inventiva, Italfarmaco, iQvia, Lilly, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Roche, Target Bio Science, and UCB in the area of potential treatments of scleroderma and its complications. In addition, Prof. Distler has a patent mir-29 for the treatment of SSc issued (US8247389, EP2331143).
Address correspondence to Dr. O. Distler, University Hospital Zurich, Department of Rheumatology, Gloriastr. 25, CH-8091 Zurich, Switzerland. Email: Oliver.Distler@usz.ch.
Accepted for publication March 6, 2020.